Vtv Therapeutics Inc – Class A (NASDAQ:VTVT) Stock Is Shorted Less

The stock of Vtv Therapeutics Inc – Class A (NASDAQ:VTVT) registered a decrease of 23.9% in short interest. VTVT’s total short interest was 869,100 shares in January as published by FINRA. Its down 23.9% from 1.14 million shares, reported previously. With 382,800 shares average volume, it will take short sellers 2 days to cover their VTVT’s short positions. The short interest to Vtv Therapeutics Inc – Class A’s float is 19.84%.

The stock decreased 1.39% or $0.04 during the last trading session, reaching $2.83. About 180,146 shares traded. vTv Therapeutics Inc. (NASDAQ:VTVT) has declined 60.34% since January 11, 2018 and is downtrending. It has underperformed by 60.34% the S&P500.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company has market cap of $122.94 million. The company??s drug candidate for the treatment of Alzheimer??s disease comprise azeliragon , an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials. It currently has negative earnings. The Company’s type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator that has been completed Phase IIb clinical trials; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which is in Phase II clinical trials.

More notable recent vTv Therapeutics Inc. (NASDAQ:VTVT) news were published by: Seekingalpha.com which released: “Healthcare & Tech dominate midday movers – Seeking Alpha” on December 28, 2018, also Seekingalpha.com with their article: “Vtv Therapeutics inks PDE4 inhibitor deal in Asia; shares up 40% premarket – Seeking Alpha” published on May 31, 2018, Benzinga.com published: “16 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” on January 02, 2019. More interesting news about vTv Therapeutics Inc. (NASDAQ:VTVT) were released by: Nasdaq.com and their article: “Pre-Market Most Active for Oct 3, 2018 : VTVT, PBR, TRI, GM, CENX, DTEA, USLV, TLRY, BILI, BABA, CGC, AA – Nasdaq” published on October 03, 2018 as well as Seekingalpha.com‘s news article titled: “VTv Therapeutics leaps 49% as it sets Alzheimer’s presentation – Seeking Alpha” with publication date: October 16, 2018.

vTv Therapeutics Inc. (NASDAQ:VTVT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.